Benign Essential Blepharospasm Research Foundation Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2020
NCT04423341
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Benign Essential Blepharospasm Research Foundation